Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans

Journal of Bone and Mineral Research

Volumn 28, Issue 5, 2013, Pages 1135-1149

  Warraich, Sumeeta ^a   Bone, Derek B J ^a,d   Quinonez, Diana ^a   Ii, Hisataka ^a   Choi, Doo Sup ^b   Holdsworth, David W ^c   Drangova, Maria ^c   Dixon, S Jeffrey ^a   Séguin, Cheryle A ^a   Hammond, James R ^a,e  

^a WESTERN UNIVERSITY   (Canada)

^b MAYO GRADUATE SCHOOL   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adenosine; Calcification; Intervertebral Disc; Micro computed Tomography; Spinal Hyperostosis

Indexed keywords

ADENOSINE; CALCIUM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; PHOSPHORUS; PYROPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKYLOSING HYPEROSTOSIS; ARTICLE; BLOOD LEVEL; CELL MEMBRANE; CONTROLLED STUDY; CORTICAL BONE; HISTOPATHOLOGY; INTERVERTEBRAL DISK; LIGAMENT; MALE; MICRO-COMPUTED TOMOGRAPHY; MINERALIZATION; MOUSE; NONHUMAN; PARALYSIS; PATHOGENESIS; PROTEIN EXPRESSION; RIGIDITY; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; STERNOCOSTAL JOINT; WILD TYPE; X RAY MICROANALYSIS;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION; HYPEROSTOSIS, DIFFUSE IDIOPATHIC SKELETAL; MICE; MICE, INBRED C57BL; SPECTROMETRY, X-RAY EMISSION; SPINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84876730179     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1826     Document Type: Article

References (65)

1. Toussaint ND., Extracellular matrix calcification in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011; 20 (4): 360-8.
2. Demer LL, Tintut Y., Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008; 117 (22): 2938-48.
3. Persy V, D'Haese P., Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009; 15 (9): 405-16.
4. Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C, Sarzi-Puttini P., Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. Rheumatology (Oxford). 2012.
5. Saetia K, Cho D, Lee S, Kim DH, Kim SD., Ossification of the posterior longitudinal ligament: a review. Neurosurg Focus. 2011; 30 (3): E1.
6. Olivieri I, D'Angelo S, Palazzi C, Padula A, Mader R, Khan MA., Diffuse idiopathic skeletal hyperostosis: differentiation from ankylosing spondylitis. Curr Rheumatol Rep. 2009; 11 (5): 321-8.
7. Resnick D, Niwayama G., Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology. 1976; 119 (3): 559-68.
8. Johnsson KE, Petersson H, Wollheim FA, Saveland H., Diffuse idiopathic skeletal hyperostosis (DISH) causing spinal stenosis and sudden paraplegia. J Rheumatol. 1983; 10 (5): 784-9.
9. Wilson FM, Jaspan T., Thoracic spinal cord compression caused by diffuse idiopathic skeletal hyperostosis (DISH). Clin Radiol. 1990; 42 (2): 133-5.
10. Seidler TO, Perez Alvarez JC, Wonneberger K, Hacki T., Dysphagia caused by ventral osteophytes of the cervical spine: clinical and radiographic findings. Eur Arch Otorhinolaryngol. 2009; 266 (2): 285-91.
11. Diederichs G, Engelken F, Marshall LM, Peters K, Black DM, Issever AS, Barrett-Connor E, Orwoll E, Hamm B, Link TM., Diffuse idiopathic skeletal hyperostosis (DISH): relation to vertebral fractures and bone density. Osteoporos Int. 2011; 22 (6): 1789-97.
12. Verdone F., Diffuse idiopathic skeletal hyperostosis in the third millennium: is there (yet) cause for concern ? J Rheumatol. 2010; 37 (6): 1356-7.
13. Kiss C, Szilagyi M, Paksy A, Poor G., Risk factors for diffuse idiopathic skeletal hyperostosis: a case-control study. Rheumatology (Oxford). 2002; 41 (1): 27-30.
14. Mader R, Lavi I., Diabetes mellitus and hypertension as risk factors for early diffuse idiopathic skeletal hyperostosis (DISH). Osteoarthritis Cartilage. 2009; 17 (6): 825-8.
15. Mader R, Novofestovski I, Adawi M, Lavi I., Metabolic syndrome and cardiovascular risk in patients with diffuse idiopathic skeletal hyperostosis. Semin Arthritis Rheum. 2009; 38 (5): 361-5.
16. Mader R., Diffuse idiopathic skeletal hyperostosis: time for a change. J Rheumatol. 2008; 35 (3): 377-9.
17. Tsukahara S, Miyazawa N, Akagawa H, Forejtova S, Pavelka K, Tanaka T, Toh S, Tajima A, Akiyama I, Inoue I., COL6A1, the candidate gene for ossification of the posterior longitudinal ligament, is associated with diffuse idiopathic skeletal hyperostosis in Japanese. Spine (Phila Pa 1976). 2005; 30 (20): 2321-4.
18. Jun JK, Kim SM., Association study of fibroblast growth factor 2 and fibroblast growth factor receptors gene polymorphism in Korean ossification of the posterior longitudinal ligament patients. J Korean Neurosurg Soc. 2012; 52 (1): 7-13.
19. Okawa A, Ikegawa S, Nakamura I, Goto S, Moriya H, Nakamura Y., Mapping of a gene responsible for twy (tip-toe walking Yoshimura), a mouse model of ossification of the posterior longitudinal ligament of the spine (OPLL). Mamm Genome. 1998; 9 (2): 155-6.
20. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S., Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998; 19 (3): 271-3.
21. Sakou T, Taketomi E, Matsunaga S, Yamaguchi M, Sonoda S, Yashiki S., Genetic study of ossification of the posterior longitudinal ligament in the cervical spine with human leukocyte antigen haplotype. Spine (Phila Pa 1976). 1991; 16 (11): 1249-52.
22. Tanaka T, Ikari K, Furushima K, Okada A, Tanaka H, Furukawa K, Yoshida K, Ikeda T, Ikegawa S, Hunt SC, Takeda J, Toh S, Harata S, Nakajima T, Inoue I., Genomewide linkage and linkage disequilibrium analyses identify COL6A1, on chromosome 21, as the locus for ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet. 2003; 73 (4): 812-22.
23. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA., Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242 (4885): 1528-34.
24. Kamiya M, Harada A, Mizuno M, Iwata H, Yamada Y., Association between a polymorphism of the transforming growth factor-beta1 gene and genetic susceptibility to ossification of the posterior longitudinal ligament in Japanese patients. Spine (Phila Pa 1976). 2001; 26 (11): 1264-6.
25. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nurnberg P., Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet. 2003; 34 (4): 379-81.
26. Armas JB, Couto AR, Bettencourt BF., Spondyloarthritis, diffuse idiopathic skeletal hyperostosis (DISH) and chondrocalcinosis. Adv Exp Med Biol. 2009; 649: 37-56.
27. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C, Mancini C, Freudenthal B, Stanescu HC, Zdebik AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, Boehm M., NT5E mutations and arterial calcifications. N Engl J Med. 2011; 364 (5): 432-42.
28. Yadav MC, Simao AM, Narisawa S, Huesa C, McKee MD, Farquharson C, Millan JL., Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res. 2011; 26 (2): 286-97.
29. Mebarek S, Hamade E, Thouverey C, Bandorowicz-Pikula J, Pikula S, Magne D, Buchet R., Ankylosing spondylitis, late osteoarthritis, vascular calcification, chondrocalcinosis and pseudo gout: toward a possible drug therapy. Curr Med Chem. 2011; 18 (14): 2196-203.
30. Evans BA., Does adenosine play a role in bone formation, resorption and repair ? Purinergic Signal. 2012; 8 (2): 177-80.
31. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD., The equilibrative nucleoside transporter family. SLC29. Pflugers Arch. 2004; 447 (5): 735-43.
32. Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, Diamond I, Bonci A, Messing RO., The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci. 2004; 7 (8): 855-61.
33. -/- mice. Am J Physiol Heart Circ Physiol. 2010; 299 (3): H847-56.
34. Weinfeld RM, Olson PN, Maki DD, Griffiths HJ., The prevalence of diffuse idiopathic skeletal hyperostosis (DISH) in two large American Midwest metropolitan hospital populations. Skeletal Radiol. 1997; 26 (4): 222-5.
35. Ulici V, Hoenselaar KD, Agoston H, McErlain DD, Umoh J, Chakrabarti S, Holdsworth DW, Beier F., The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. Bone. 2009; 45 (6): 1133-45.
36. Feldkamp LA, Davis LC, Kress JW., Practical cone-beam algorithm. J Opt Soc Am A. 1984; 1 (6): 612-9.
37. Miller LM, Little W, Schirmer A, Sheik F, Busa B, Judex S., Accretion of bone quantity and quality in the developing mouse skeleton. J Bone Miner Res. 2007; 22 (7): 1037-45.
38. Costa DO, Allo BA, Klassen R, Hutter JL, Dixon SJ, Rizkalla AS., Control of surface topography in biomimetic calcium phosphate coatings. Langmuir. 2012; 28 (8): 3871-80.
39. Ramakers BP, Pickkers P, Deussen A, Rongen GA, van den Broek P, van der Hoeven JG, Smits P, Riksen NP., Measurement of the endogenous adenosine concentration in humans in vivo: methodological considerations. Curr Drug Metab. 2008; 9 (8): 679-85.
40. Xu L, Farthing AK, Shi YJ, Meinke PT, Liu K., Conversion of nocathiacin I to nocathiacin acid by a mild and selective cleavage of dehydroalanine. J Org Chem. 2007; 72 (19): 7447-50.
41. Rose JB, Naydenova Z, Bang A, Ramadan A, Klawitter J, Schram K, Sweeney G, Grenz A, Eltzschig H, Hammond J, Choi DS, Coe IR., Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge. Life Sci. 2011; 89 (17-18): 621-30.
42. Guillen-Gomez E, Pinilla-Macua I, Perez-Torras S, Choi DS, Arce Y, Ballarin JA, Pastor-Anglada M, Diaz-Encarnacion MM., New role of the human equilibrative nucleoside transporter 1 (hENT1) in epithelial-to-mesenchymal transition in renal tubular cells. J Cell Physiol. 2012; 227 (4): 1521-8.
43. Chen J, Rinaldo L, Lim SJ, Young H, Messing RO, Choi DS., The type 1 equilibrative nucleoside transporter regulates anxiety-like behavior in mice. Genes Brain Behav. 2007; 6 (8): 776-83.
44. Rose JB, Naydenova Z, Bang A, Eguchi M, Sweeney G, Choi DS, Hammond JR, Coe IR., Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection. Am J Physiol Heart Circ Physiol. 2010; 298 (3): H771-7.
45. Grenz A, Bauerle JD, Dalton JH, Ridyard D, Badulak A, Tak E, McNamee EN, Clambey E, Moldovan R, Reyes G, Klawitter J, Ambler K, Magee K, Christians U, Brodsky KS, Ravid K, Choi DS, Wen J, Lukashev D, Blackburn MR, Osswald H, Coe IR, Nurnberg B, Haase VH, Xia Y, Sitkovsky M, Eltzschig HK., Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest. 2012; 122 (2): 693-710.
46. Urban JP, Smith S, Fairbank JC., Nutrition of the intervertebral disc. Spine (Phila Pa 1976). 2004; 29 (23): 2700-9.
47. Freemont TJ, LeMaitre C, Watkins A, Hoyland JA., Degeneration of intervertebral discs: current understanding of cellular and molecular events, and implications for novel therapies. Expert Rev Mol Med. 2001; 2001: 1-10.
48. Jarvis SM, Hammond JR, Paterson AR, Clanachan AS., Species differences in nucleoside transport. A study of uridine transport nitrobenzylthioinosine binding by mammalian erythrocytes. Biochem J. 1982; 208 (1): 83-8.
49. Terkeltaub R., Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2006; 2 (2): 371-7.
50. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millan JL., Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004; 164 (4): 1199-209.
51. Ho AM, Johnson MD, Kingsley DM., Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000; 289 (5477): 265-70.
52. Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun HS, Laing N, Tinschert S., Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001; 28 (1): 37-41.
53. Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, Baur ST, Shiang R, Grange DK, Beighton P, Gardner J, Hamersma H, Sellars S, Ramesar R, Lidral AC, Sommer A, Raposo do, Amaral CM, Gorlin RJ, Mulliken JB, Olsen BR., Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001; 68 (6): 1321-6.
54. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley DM., Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet. 2002; 71 (4): 933-40.
55. Williams CJ, Zhang Y, Timms A, Bonavita G, Caeiro F, Broxholme J, Cuthbertson J, Jones Y, Marchegiani R, Reginato A, Russell RG, Wordsworth BP, Carr AJ, Brown MA., Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet. 2002; 71 (4): 985-91.
56. Barvencik F, Beil FT, Gebauer M, Busse B, Koehne T, Seitz S, Zustin J, Pogoda P, Schinke T, Amling M., Skeletal mineralization defects in adult hypophosphatasia-a clinical and histological analysis. Osteoporos Int. 2011; 22 (10): 2667-75.
57. Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE., International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev. 2011; 63 (1): 1-34.
58. Armstrong S, Korcok J, Sims SM, Dixon SJ., Activation of transcription factors by extracellular nucleotides in immune and related cell types. Purinergic Signal. 2007; 3 (1-2): 59-69.
59. Grol MW, Panupinthu N, Korcok J, Sims SM, Dixon SJ., Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal. 2009; 5 (2): 205-21.
60. Gharibi B, Abraham AA, Ham J, Evans BA., Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. J Bone Miner Res. 2011; 26 (9): 2112-24.
61. Prosdocimo DA, Wyler SC, Romani AM, O'Neill WC, Dubyak GR., Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol. 2010; 298 (3): C702-13.
62. Panupinthu N, Rogers JT, Zhao L, Solano-Flores LP, Possmayer F, Sims SM, Dixon SJ., P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis. J Cell Biol. 2008; 181 (5): 859-71.
63. Resnick D, Guerra J Jr, Robinson CA, Vint VC., Association of diffuse idiopathic skeletal hyperostosis (DISH) and calcification and ossification of the posterior longitudinal ligament. AJR Am J Roentgenol. 1978; 131 (6): 1049-53.
64. Parker VS, Malhotra CM, Ho G Jr, Kaplan SR., Radiographic appearance of the sternomanubrial joint in arthritis and related conditions. Radiology. 1984; 153 (2): 343-7.
65. Verlaan JJ, Westerveld LA, van Keulen JW, Bleys RL, Dhert WJ, van Herwaarden JA, Moll FL, Oner FC., Quantitative analysis of the anterolateral ossification mass in diffuse idiopathic skeletal hyperostosis of the thoracic spine. Eur Spine J. 2011; 20 (9): 1474-9.